PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-64.40%
Cash & equivalents declining -64.40% while AGEN's grows 144.55%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Below half of AGEN's 89.57%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Below half of AGEN's 81.86%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Below half of AGEN's 35.21%. Michael Burry sees a potential red flag for stagnation or capital shortage.
289.39%
Above 1.5x AGEN's 9.03%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Exceeding 1.5x AGEN's 42.66%. Michael Burry suspects ballooning short-term obligations vs. competitor.
357.80%
Less than half of AGEN's -5.49%. David Dodd sees a more disciplined short-term liability approach.
8.45%
Higher Long-Term Debt Growth compared to AGEN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.45%
Less than half of AGEN's -0.46%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
40.87%
Less than half of AGEN's -0.92%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-9.75%
≥ 1.5x AGEN's -2.22%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
-29.17%
Less than half of AGEN's 36.62%. David Dodd notes simpler yoy equity changes vs. competitor.
-61.26%
Below half AGEN's 35.11%. Michael Burry sees potential underperformance in building shareholder capital.
-64.40%
Below half AGEN's 35.21%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
8.45%
Higher Total Debt Growth compared to AGEN's zero value, indicating worse performance.
24.32%
Less than half of AGEN's -33.19%. David Dodd sees better deleveraging or stronger cash buildup than competitor.